Oops, you're using an old version of your browser so some of the features on this page may not be displaying properly.

MINIMAL Requirements: Google Chrome 24+Mozilla Firefox 20+Internet Explorer 11Opera 15–18Apple Safari 7SeaMonkey 2.15-2.23

ESMO Virtual Advanced Course on Applying Latest Advances in Clinic for GI Cancers 2022

23 - 24 Jun 2022

ESMO-Virtual-Advanced-Courses-GI-Cancers-1000x1000

Slides and webcasts from all ESMO Advanced Courses are open to ESMO Members and course attendees, according to the presenters' agreement to release them. ESMO thanks the authors for their generosity.

The use of these presentations is for personal educational purposes only.

Learning objectives
  • To understand the utility of liquid biopsies and treatment in early colorectal cancer
  • To learn about the differences between long course vs short course approaches for rectal cancers.
  • To learn about making treatment choices in advanced HCC
  • To learn about the latest in immunotherapy and anti-HER2 therapies in upper GI cancers
  • To understand the current and novel therapies for advanced BTC
  • To understand treatment approaches for oligometastatic oesophageal cancer
  • To learn about the data for neoadjuvant, adjuvant and peri-op treatment of resectable pancreas cancer
Hide
Filter by:

There are 10 resources available

Welcome and course overview

Presenter: S.P. Choo, SG, H. van Laarhoven, NL

Session: Welcome and course overview

Resources:

Slides

Webcast

Metastatic MSI-high CRC

Presenter: T. Yoshino, JP

Session: Session 1 - Colorectal cancer

Resources:

Slides

Webcast

This site uses cookies. Some of these cookies are essential, while others help us improve your experience by providing insights into how the site is being used.

For more detailed information on the cookies we use, please check our Privacy Policy.

Customise settings
  • Necessary cookies enable core functionality. The website cannot function properly without these cookies, and you can only disable them by changing your browser preferences.